Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

In a report released today, Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Messenger Ribonucleic Acid (mRNA) vaccines gained global recognition during the Coronavirus Disease 2019 (COVID-19) pandemic, proving their value through rapid development, high efficacy ...

In a press release issued at the time, Zieler said, “We are excited to work with ExPLoRNA to bring industry leading mRNA cap analogs to the market and pairing them with Primrose Bio's RNA polymerases.

Sunshine Biopharma's K1.1 mRNA-LNP reduced human HCC tumor growth in mice with good tolerability under repeated dosing. The company's 2024 revenue rose 45% year over year to $34.9 million.